Literature DB >> 1827667

A study of chromosome 11p13 translocations involving TCR beta and TCR delta in human T cell leukaemia.

I S Garcia1, Y Kaneko, R Gonzalez-Sarmiento, K Campbell, L White, T Boehm, T H Rabbitts.   

Abstract

A frequent site of translocation damage in human T-ALL has been localized to a specific region of chromosome band 11p13. Five new T-ALL cases are described which break in the major T-ALLbcr region of 11p13, two involving a novel translocation t(7;11)(q35;p13), with breakage at the T cell receptor (TCR) beta gene from 7q35, and three involving TCR delta from 14q11 in the more common t(11;14)(p13;q11). Analysis of the mechanism of one T-ALLbcr/TCR beta translocation and a previously described t(11;14)(p13;q11) was conducted by genomic cloning of translocation breakpoints, using the polymerase chain reaction (PCR). Both seem to have occurred by recombinase error, but only the t(7;11) showed sequence-specific joining. Nonetheless recombinase mediation of the t(11;14) is implied by the presence of N-region addition (a hallmark of recombinase joins) on both derivative chromosomes. These observations reinforce the view that translocations in the T-ALLbcr region of chromosome 11p13 are a major lesion in human T-ALL. In addition, these can occur by mimicry of VDJ joining, but sequence specificity is not obligatory.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827667

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  HOX11, a homeobox-containing T-cell oncogene on human chromosome 10q24.

Authors:  M A Kennedy; R Gonzalez-Sarmiento; U R Kees; F Lampert; N Dear; T Boehm; T H Rabbitts
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

2.  A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice.

Authors:  K M Draheim; N Hermance; Y Yang; E Arous; J Calvo; M A Kelliher
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

Review 3.  Stem cell manipulation, gene therapy and the risk of cancer stem cell emergence.

Authors:  Flora Clément; Elodie Grockowiak; Florence Zylbersztejn; Gaëlle Fossard; Stéphanie Gobert; Véronique Maguer-Satta
Journal:  Stem Cell Investig       Date:  2017-07-25

4.  Null mutation of the Lmo4 gene or a combined null mutation of the Lmo1/Lmo3 genes causes perinatal lethality, and Lmo4 controls neural tube development in mice.

Authors:  E Tse; A J H Smith; S Hunt; I Lavenir; A Forster; A J Warren; G Grutz; L Foroni; M B L Carlton; W H Colledge; T Boehm; T H Rabbitts
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

5.  The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development.

Authors:  Matthew P McCormack; Alan Forster; Lesley Drynan; Richard Pannell; Terence H Rabbitts
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

6.  The cysteine-rich LIM domains inhibit DNA binding by the associated homeodomain in Isl-1.

Authors:  I Sánchez-García; H Osada; A Forster; T H Rabbitts
Journal:  EMBO J       Date:  1993-11       Impact factor: 11.598

7.  V(D)J-mediated translocations in lymphoid neoplasms: a functional assessment of genomic instability by cryptic sites.

Authors:  Rodrig Marculescu; Trang Le; Paul Simon; Ulrich Jaeger; Bertrand Nadel
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

8.  The LMO2 -25 Region Harbours GATA2-Dependent Myeloid Enhancer and RUNX-Dependent T-Lymphoid Repressor Activity.

Authors:  Nicolas Bonadies; Berthold Göttgens; Fernando J Calero-Nieto
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

Review 9.  LMO2 at 25 years: a paradigm of chromosomal translocation proteins.

Authors:  Jennifer Chambers; Terence H Rabbitts
Journal:  Open Biol       Date:  2015-06       Impact factor: 6.411

10.  Upstream distal regulatory elements contact the Lmo2 promoter in mouse erythroid cells.

Authors:  Anandi Bhattacharya; Chih-Yu Chen; Sara Ho; Jennifer A Mitchell
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.